In a significant move underscoring its commitment to healthcare innovation, Mumbai-based pharmaceutical titan Lupin Limited has secured tentative approval from the United States Food and Drug Administration (USFDA) for their Oxcarbazepine Extended-Release (ER) tablets. This milestone is not only a testament to Lupin’s relentless drive in the search for better treatment options for seizure disorders but also a strong indicator of the company’s prowess in pharmaceutical innovation and its resolve to address unmet medical needs globally.
Lupin’s Oxcarbazepine ER product, a bioequivalent to Oxtellar XR ER Tablets of Supernus Pharmaceuticals, Inc., is indicated for the treatment of partial-onset seizures in patients aged six and older. This is a significant development in the realm of neurology, addressing a critical need in seizure management. The medication is expected to be manufactured at Lupin’s state-of-the-art Nagpur facility in India, further reinforcing the company’s robust manufacturing capabilities.
With a diverse portfolio encompassing branded and generic formulations, biotechnology products, and active pharmaceutical ingredients, Lupin has carved a niche for itself in over 100 markets worldwide. The company’s strong foothold, particularly in the U.S. and India, across therapy areas such as respiratory, cardiovascular, anti-diabetic, and central nervous system, is a testament to its dedication in delivering high-quality healthcare solutions.
The approval of Oxcarbazepine ER is a substantial step forward in Lupin’s mission to expand its global market reach and address significant unmet medical needs. The product had estimated annual sales of USD 206 million in the U.S. as of April 2025 (IQVIA MAT), indicating its potential to be a game-changer in the neurology segment.
The latest development is a strategic addition to Lupin’s growing portfolio of generic neurology drugs in the U.S. market, following the approval of Eslicarbazepine Acetate Tablets earlier in May. With 15 cutting-edge manufacturing facilities and 7 research centers strategically positioned across the globe, Lupin is well-poised to drive growth and make a positive impact on the healthcare landscape.
As Lupin Limited continues its trajectory of innovation and excellence in the pharmaceutical industry, its commitment to improving patient outcomes remains unwavering. This recent milestone is not just another feather in Lupin’s cap, but a demonstration of how pharmaceutical businesses can make a profound difference in healthcare by addressing unmet needs, providing high-quality solutions, and continually pushing the boundaries of innovation.
Read more from medicaldialogues.in
